Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
The Botnar Institute of Immune Engineering (BIIE) is a new interdisciplinary research institute dedicated to innovation in immune engineering. Founded in 2024 through a generous endowment from Fondation Botnar, the BIIE supports scientists in taking on
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
At EY, we’re all in to shape your future with confidence. We’ll help you succeed in a globally connected powerhouse of diverse teams and take your career wherever you want it to go. Join EY and
Location: Basel, Switzerland Contract Duration: 3 years, with possible extension Experience Required: 3+ years. Industry Experience: Utilities & Energy (Energie & Wasserversorgung) or Telecommunications or Banking & Financial Services or Information Technology & Services Role Overview
Location: Basel, Switzerland Contract Duration: 3 years, with possible extension Experience Required: 3+ years. Industry Experience: Utilities & Energy (Energie & Wasserversorgung) or Telecommunications or Banking & Financial Services or Information Technology & Services Role Overview
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
The Botnar Institute of Immune Engineering (BIIE) is a new interdisciplinary research institute dedicated to innovation in immune engineering. Founded in 2024 through a generous endowment from Fondation Botnar, the BIIE supports scientists in taking on